Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Non-Current Deferred Tax Liability (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $811000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 81.75% to $811000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $811000.0 through Dec 2025, down 81.75% year-over-year, with the annual reading at $811000.0 for FY2025, 81.75% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $811000.0 at Nuvation Bio, down from $4.4 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $4.4 million in Q4 2024, with the low at $811000.0 in Q4 2025.
  • Average Non-Current Deferred Tax Liability over 3 years is $2.1 million, with a median of $931000.0 recorded in 2023.
  • The sharpest move saw Non-Current Deferred Tax Liability skyrocketed 377.34% in 2024, then tumbled 81.75% in 2025.
  • Over 3 years, Non-Current Deferred Tax Liability stood at $931000.0 in 2023, then surged by 377.34% to $4.4 million in 2024, then crashed by 81.75% to $811000.0 in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $811000.0, $4.4 million, and $931000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.